Sterling Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Sterling Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.48K	Sell	238 -75	-24%	-$556	﹤0.01%	2936
2026 Q1	$1.93K	Sell	313 -331	-51%	-$2.36K	﹤0.01%	3003
2025 Q4	$4.64K	Buy	644 +5	+0.8%	+$40	﹤0.01%	2914
2025 Q3	$6.53K	Buy	639 +416	+187%	+$4.68K	﹤0.01%	2689
2025 Q2	$2.32K	Buy	223 +209	+1,493%	+$2.23K	﹤0.01%	2883
2025 Q1	$185	Hold	14	–	–	﹤0.01%	3092
2024 Q4	$251	Buy	14 +7	+100%	+$142	﹤0.01%	3102
2024 Q3	$113	Buy	+7	New	+$109	﹤0.01%	3183

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's RNAC Position: Q2 2026 in Review

Sterling Capital Management reduced its Cartesian Therapeutics (RNAC) stake by 24% in Q2 2026, selling an estimated $556 and leaving 238 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Sterling Capital Management first reported a position in RNAC in Q3 2024 and has held it in 8 quarters since. The position peaked at $6.53K in Q3 2025. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Sterling Capital Management held 238 shares of Cartesian Therapeutics worth $2.48K as of Q2 2026.
Sterling Capital Management sold 75 Cartesian Therapeutics shares in Q2 2026, an estimated $556.
Cartesian Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2936 holding.
Sterling Capital Management first reported a position in Cartesian Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Cartesian Therapeutics position peaked at $6.53K in Q3 2025.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.